NCT00571506View on ClinicalTrials.gov

Effect of Thiazolidinedione Treatment Vascular Risk Markers

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Diabetes Mellitus, Type 2Vascular Diseases
Interventions
DRUG

Rosiglitazone

Rosiglitazone 4 mg tablets by mouth daily for 3 months

DRUG

Pioglitazone

Pioglitazone 30 mg tablet by mouth once daily

Trial Locations (1)

72205

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors
lead

University of Arkansas

OTHER

NCT00571506 - Effect of Thiazolidinedione Treatment Vascular Risk Markers | Biotech Hunter | Biotech Hunter